Brief: Sensorion Updates On SENS-401 Phase 2 Trial In Sudden Sensorineural Hearing Loss

Sensorion SA

17/01/2022 06:37

Jan 17 (Reuters) - Sensorion SA  ALSEN.PA :
    * UPDATES ON SENS-401 PHASE 2 TRIAL IN SUDDEN SENSORINEURAL
HEARING LOSS
    * SAFE AND WELL TOLERATED IN 115-PATIENT SSNHL STUDY;
PRIMARY
ENDPOINT NOT MET
    * SENSORION CONTINUES TO DEVELOP SENS-401 IN OTHER
INDICATIONS
    * SENSORION WILL CONTINUE TO ANALYZE DATA FROM AUDIBLE-S
STUDY AND
UPDATE MARKET MID-MARCH FOLLOWING ANALYSIS OF SECONDARY
ENDPOINTS
    * THREE PRECLINICAL GENE THERAPY PROGRAMS, AIMED AT
CORRECTING
HEREDITARY MONOGENIC FORMS OF DEAFNESS, ARE IN PROGRESS
    * SENSORION AND ITS PARTNER COCHLEAR LIMITED PLAN TO SUBMIT
A
CLINICAL TRIAL APPLICATION FOR SENS-401 IN PATIENTS SCHEDULED
FOR COCHLEAR IMPLANTATION BY END OF JANUARY 2022

Source text for Eikon:  ID:nBw3Jvl25a 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))